Acquired necrotizing myopathies;Les myopathies nécrosantes acquises

Revue de Medecine Interne

Volumn 34, Issue 6, 2013, Pages 363-368

  Allenbach, Y ^a   Benveniste, O ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Muscular disease; Necrotizing myopathy; Paraneoplasic myopathy; SRP

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT;

ACQUIRED NECROTIZING MYOPATHY; AUTOIMMUNE DISEASE; CONNECTIVE TISSUE DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; HEART DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; MUSCULAR DYSTROPHY; MYOPATHY; MYOSITIS; SCLERODERMA; SHORT SURVEY; WEAKNESS;

EID: 84878137196     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.07.018     Document Type: Short Survey

References (39)

1. Mc C.R., Mac M.H. Dermatomyositis associates with metastasizing bronchogenic carcinoma; a clinicopathological conference. Med Clin North Am 1947, 31:1148-1162.
2. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
3. Targoff I.N., Johnson A.E., Miller F.W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990, 33:1361-1370.
4. Kao A.H., Lacomis D., Lucas M., Fertig N., Oddis C.V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004, 50:209-215.
5. Bronner I.M., Hoogendijk J.E., Wintzen A.R., van der Meulen M.F., Linssen W.H., Wokke J.H., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003, 250:480-485.
6. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63:713-721.
7. Levin M.I., Mozaffar T., Al-Lozi M.T., Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998, 50:764-767.
8. Ellis E., Ann Tan J., Lester S., Tucker G., Blumbergs P., Roberts-Thomson P., et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 2012, 45:189-194.
9. Brouwer R., Hengstman G.J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
10. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
11. Reeves W.H., Nigam S.K., Blobel G. Human autoantibodies reactive with the signal recognition particle. Proc Natl Acad Sci U S A 1986, 83:9507-9511.
12. Hengstman G.J., ter Laak H.J., Vree Egberts W.T., Lundberg I.E., Moutsopoulos H.M., Vencovsky J., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006, 65:1635-1638.
13. Miller T., Al-Lozi M.T., Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002, 73:420-428.
14. Suzuki S., Satoh T., Sato S., Otomo M., Hirayama Y., Sato H., et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008, 47:1539-1542.
15. Rouster-Stevens K.A., Pachman L.M. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008, 35(5):927-929.
16. Bloch-Queyrat C., Rigolet A., Dubourg O., Laforet P., Costedoat-Chalumeau N., Grenier P., et al. Les myopathies à anticorps anti-SRP: caractérisation et suivi de 24 patients. Rev Med Interne 2009, 30(Suppl. 2):S46.
17. Dimitri D., Andre C., Roucoules J., Hosseini H., Humbel R.L., Authier F.J. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007, 35:389-395.
18. Shirai Y., Koizumi K., Ogawa R., Suzuki T., Koido N., Ohosone Y., et al. Anti-signal recognition particle (SRP) antibody positive polymyositis refractory to corticosteroid treatment. Nihon Naika Gakkai Zasshi 2007, 96:2522-2524.
19. Vincze M., Molnar P.A., Tumpek J., Szollosi L., Gyetvai A., Kapitany A., et al. An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol 2010, 29:811-814.
20. Romisch K., Miller F.W., Dobberstein B., High S. Human autoantibodies against the 54kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006, 8:R39.
21. Benveniste O., Drouot L., Jouen F., Charuel J.L., Bloch-Queyrat C., Behin A., et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011, 63:1961-1971.
22. Arlet J.B., Dimitri D., Pagnoux C., Boyer O., Maisonobe T., Authier F.J., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006, 16:334-336.
23. Valiyil R., Casciola-Rosen L., Hong G., Mammen A., Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010, 62:1328-1334.
24. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63:713-721.
25. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
26. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
27. Mammen A.L., Pak K., Williams E.K., Brisson D., Coresh J., Selvin E., et al. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care Res (Hoboken) 2012, 64:269-272.
28. Ranque B., Authier F.J., Le-Guern V., Pagnoux C., Berezne A., Allanore Y., et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009, 68:1474-1477.
29. Ranque B., Berezne A., Le-Guern V., Pagnoux C., Allanore Y., Launay D., et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol 2010, 39:498-505.
30. Sarui H., Maruyama T., Ito I., Yamakita N., Takeda N., Nose M., et al. Necrotising myositis in Behcet's disease: characteristic features on magnetic resonance imaging and a review of the literature. Ann Rheum Dis 2002, 61:751-752.
31. Smith B. Skeletal muscle necrosis associated with cainoma. J Pathol 1969, 97:207-210.
32. Sampson J.B., Smith S.M., Smith A.G., Singleton J.R., Chin S., Pestronk A., et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007, 17:404-408.
33. Emslie-Smith A.M., Engel A.G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991, 41:936-939.
34. Hicks D., Sarkozy A., Muelas N., Koehler K., Huebner A., Hudson G., et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011, 134(Pt 1):171-182.
35. Benveniste O., Romero N.B. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011, 40(4 Pt 2):e249-e255.
36. Melli G., Chaudhry V., Cornblath D.R. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005, 84:377-385.
37. Gaist D., Rodriguez L.A., Huerta C., Hallas J., Sindrup S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569.
38. Silva M.A., Swanson A.C., Gandhi P.J., Tataronis G.R. Statin-related adverse events: a meta-analysis. Clin Ther 2006, 28:26-35.
39. Kuncl R.W. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009, 22:506-515.